The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 18 rounds in the feed, most often in Biotech.
Private equityanderapartners.comRounds from 2018-04-18 to 2026-10-19
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Nouscom Nouscom is a biotech company selling cancer-preventing vaccine candidates primarily to healthcare providers and clinical trial organizations. | Series D Verified against 4 of 10 sources | $133.8M | 2026-10-19 | [ PART ] |
Nouscom A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies | Series D |
| $134.7M |
| 2026-10-19 |
| [ PART ] |
HighLife HighLife develops a transcatheter system for replacing the mitral valve in patients with heart valve disease. | Funding round Verified against 4 of 9 sources | $90M | 2026-09-22 | [ LEAD ] |
Alveus Therapeutics Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases. | Series A ext. Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $197M financing total | 2026-02-24 | [ LEAD ] |
Alveus Therapeutics Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $160M | 2026-01-08 | [ LEAD ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-11-17 | [ PART ] |
ADCytherix Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $122.3M | 2025-10-16 | [ LEAD ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $358.0M | 2025-10-15 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $139.8M | 2024-03-14 | [ PART ] |
MMI (Medical Microinstruments) A surgical-robotics company that makes the Symani system for microsurgery and super-microsurgery | Series C Developing, 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2024-02-21 | [ PART ] |
Nouscom Nouscom is a biotech company selling cancer-preventing vaccine candidates primarily to healthcare providers and clinical trial organizations. | Series C Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $72.4M | 2023-11-14 | [ LEAD ] |
Nouscom A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $72.4M | 2023-11-14 | [ LEAD ] |
MMI (Medical Microinstruments) A surgical-robotics company that makes the Symani system for microsurgery and super-microsurgery | Series B Verified against 1 of 5 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2022-07-20 | [ PART ] |
Tubulis Tubulis develops antibody-drug conjugates for treating various cancers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $63.3M | 2022-05-03 | [ LEAD ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $153M | 2021-07-27 | [ PART ] |
HighLife HighLife develops a transcatheter system for replacing the mitral valve in patients with heart valve disease. | Series B Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $36.5M | 2019-01-17 | [ LEAD ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $84M | 2018-08-10 | [ LEAD ] |
MMI (Medical Microinstruments) A surgical-robotics company that makes the Symani system for microsurgery and super-microsurgery | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $24.8M | 2018-04-18 | [ LEAD ] |